Journal of Medicinal Chemistry, volume 45, issue 20, pages 4505-4512
Enhancement of Nucleoside Cytotoxicity through Nucleotide Prodrugs
Jerry D. Rose
1
,
William B. Parker
1
,
Hitoshi Someya
1
,
Sue C Shaddix
1
,
John A. Montgomery
1
,
John A. Secrist
1
1
Southern Research Institute, P.O. Box 55305, Birmingham, Alabama 35255-5305
|
Publication type: Journal Article
Publication date: 2002-08-24
Journal:
Journal of Medicinal Chemistry
scimago Q1
SJR: 1.986
CiteScore: 12.8
Impact factor: 6.8
ISSN: 00222623, 15204804
PubMed ID:
12238929
Drug Discovery
Molecular Medicine
Abstract
A common reason for the lack of cytotoxicity of certain nucleosides is thought to be their inability to be initially activated to the monophosphate level by a nucleoside kinase or other activating enzyme. In a search for other nucleosides that might be worthwhile anticancer agents, we have begun to examine the utilization of monophosphate prodrugs in order to explore whether any enhanced cytotoxicity might be found for the prodrugs of candidate nucleosides that have little or no cytotoxicity. To that end, 5'-bis(pivaloyloxymethyl) phosphate prodrugs of two weakly cytotoxic compounds, 8-aza-2'-deoxyadenosine (5) and 8-bromo-2'-deoxyadenosine (9), have been prepared. These prodrugs (8 and 12) were examined for their cytotoxicity in CEM cells and were found to possess significantly enhanced cytotoxicity when compared with the corresponding parent nucleosides. Further cell culture experiments were conducted to gain insight into the mechanisms of cytotoxicity of these two prodrugs, and those data are reported.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.